Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorZYSMAN, Maeva
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRAHERISON-SEMJEN, Chantal
dc.date.accessioned2022-03-08T16:45:57Z
dc.date.available2022-03-08T16:45:57Z
dc.date.issued2022
dc.identifier.issn2296-858Xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/136390
dc.description.abstractEnChronic obstructive pulmonary disease (COPD) is no longer a respiratory disease that predominantly affects men, to the point where the prevalence among women has equaled that of men since 2008, partly due to their increasing exposure to tobacco and to biomass fuels. Indeed, COPD has become the leading cause of death in women in the USA. A higher susceptibility of female to smoking and pollutants could explain this phenomenon. Besides, the clinical presentation appears different among women with more frequent breathlessness, anxiety or depression, lung cancer (especially adenocarcinoma), undernutrition and osteoporosis. Quality of life is also more significantly impaired in women. The theories advanced to explain these differences involve the role of estrogens, smaller bronchi, impaired gas exchange in the lungs and smoking habits. Usual medications (bronchodilators, ICS) demonstrated similar trends for exacerbation prevention and lung function improvement in men and women. There is an urgent need to recognize the increasing burden of COPD in women and therefore to facilitate global improvements in disease management (smoking cessation, pulmonary rehabilitation...) in half of the population. Nevertheless, important limitations to the treatment of women with COPD include greater under-diagnosis than in men, fewer spirometry tests and medical consultations. In conclusion there is an urgent need to recognize the increasing burden of COPD in women and therefore to facilitate globally improvements in disease management in this specific population.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enChronic obstructive pulmonary disease (COPD)
dc.subject.enGender
dc.subject.enEpidemiology
dc.subject.enSmoking
dc.subject.enPerspective
dc.title.enWomen's COPD
dc.typeArticle de revueen_US
dc.identifier.doi10.3389/fmed.2021.600107en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed35047517en_US
bordeaux.journalFrontiers in Medicineen_US
bordeaux.page600107en_US
bordeaux.volume8en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03602130
hal.version1
hal.date.transferred2022-03-08T16:45:59Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers%20in%20Medicine&rft.date=2022&rft.volume=8&rft.spage=600107&rft.epage=600107&rft.eissn=2296-858X&rft.issn=2296-858X&rft.au=ZYSMAN,%20Maeva&RAHERISON-SEMJEN,%20Chantal&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée